Interactions between peroxisome proliferator-activated receptor-[gamma] 2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication
Interactions between peroxisome proliferator-activated receptor-[gamma] 2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication
Objective: The combination of small birth size and the Pro12Pro variant of the peroxisome proliferator-activated receptor-[gamma]2 (PPAR-[gamma]2) gene has been shown to be associated with insulin resistance, which is linked to hypertension. We examined whether the association between small body size at birth and adult blood pressure is modulated by PPAR-[gamma]2 gene polymorphism, and whether the use of any class of antihypertensive medication is related to birth size.
Design and Methods: A total of 500 subjects from an original epidemiological cohort of 7086 men and women aged 65-75 years attended a clinical study. Two hundred and eight of them (73 men and 135 women) were taking antihypertensive medication and are included in this study. The Pro12Ala polymorphism of the PPAR-[gamma]2 gene was determined using the polymerase chain reaction single-strand conformation polymorphism method.
Results and Conclusions: Hypertensive subjects with low birth weight or short length at birth and the Pro12Pro variant had raised systolic blood pressure. We suggest that insulin resistance enhances the regulatory responses of the renin-angiotensin system, leading to raised blood pressure levels. Those hypertensive subjects who had small birth size and the Pro12Pro variant tended to use angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers (ACEI/ARB). This could be because insulin resistance interacts with the renin-angiotensin system in ways that make ACEI/ARB an effective therapy. Alternative explanations include more severe and teatment resistant hypertension, leading to application of ACEI/ARB, or co-morbid conditions, such as myocardial infarction and type 2 diabetes, known to be linked to low birth weight.
1283-1287
Yliharsila, H.
fcc22917-d02b-4b3f-b5f7-500edaa51503
Eriksson, J.G.
eda300d2-b247-479f-95b9-f12d2c72e92b
Forsen, T.
009ce53c-8bbf-4c5c-a21f-0bbdd1f999c4
Laakso, M.
ec6734f9-b924-430e-89a0-47fa5c66110d
Uusitupa, M.
0b80be97-ba89-475e-aa3b-b440470357d6
Osmond, C.
2677bf85-494f-4a78-adf8-580e1b8acb81
Barker, D.J.P.
64c6005a-eea7-4c26-8f07-50d875998512
2004
Yliharsila, H.
fcc22917-d02b-4b3f-b5f7-500edaa51503
Eriksson, J.G.
eda300d2-b247-479f-95b9-f12d2c72e92b
Forsen, T.
009ce53c-8bbf-4c5c-a21f-0bbdd1f999c4
Laakso, M.
ec6734f9-b924-430e-89a0-47fa5c66110d
Uusitupa, M.
0b80be97-ba89-475e-aa3b-b440470357d6
Osmond, C.
2677bf85-494f-4a78-adf8-580e1b8acb81
Barker, D.J.P.
64c6005a-eea7-4c26-8f07-50d875998512
Yliharsila, H., Eriksson, J.G., Forsen, T., Laakso, M., Uusitupa, M., Osmond, C. and Barker, D.J.P.
(2004)
Interactions between peroxisome proliferator-activated receptor-[gamma] 2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication.
Journal of Hypertension, 22 (7), .
Abstract
Objective: The combination of small birth size and the Pro12Pro variant of the peroxisome proliferator-activated receptor-[gamma]2 (PPAR-[gamma]2) gene has been shown to be associated with insulin resistance, which is linked to hypertension. We examined whether the association between small body size at birth and adult blood pressure is modulated by PPAR-[gamma]2 gene polymorphism, and whether the use of any class of antihypertensive medication is related to birth size.
Design and Methods: A total of 500 subjects from an original epidemiological cohort of 7086 men and women aged 65-75 years attended a clinical study. Two hundred and eight of them (73 men and 135 women) were taking antihypertensive medication and are included in this study. The Pro12Ala polymorphism of the PPAR-[gamma]2 gene was determined using the polymerase chain reaction single-strand conformation polymorphism method.
Results and Conclusions: Hypertensive subjects with low birth weight or short length at birth and the Pro12Pro variant had raised systolic blood pressure. We suggest that insulin resistance enhances the regulatory responses of the renin-angiotensin system, leading to raised blood pressure levels. Those hypertensive subjects who had small birth size and the Pro12Pro variant tended to use angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers (ACEI/ARB). This could be because insulin resistance interacts with the renin-angiotensin system in ways that make ACEI/ARB an effective therapy. Alternative explanations include more severe and teatment resistant hypertension, leading to application of ACEI/ARB, or co-morbid conditions, such as myocardial infarction and type 2 diabetes, known to be linked to low birth weight.
This record has no associated files available for download.
More information
Published date: 2004
Identifiers
Local EPrints ID: 26146
URI: http://eprints.soton.ac.uk/id/eprint/26146
ISSN: 0263-6352
PURE UUID: bdda65b2-8742-4cf1-9d30-78153211e735
Catalogue record
Date deposited: 12 Apr 2006
Last modified: 23 Jul 2022 01:39
Export record
Contributors
Author:
H. Yliharsila
Author:
J.G. Eriksson
Author:
T. Forsen
Author:
M. Laakso
Author:
M. Uusitupa
Author:
D.J.P. Barker
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics